StreetInsider.com News Articles

Humacyte (HUMA) PT Lowered to $1.25 at TD Cowen

Wed, 17 Jun 2026 08:28:32 -0400

TD Cowen analyst Joshua Jennings lowered the price target on Humacyte (NASDAQ: HUMA) to $1.25 (from $1.50) while maintaining a Buy rating.

Form SCHEDULE 13D/A Humacyte, Inc. Filed by: FRESENIUS MEDICAL CARE HOLDINGS INC /NY/

Mon, 15 Jun 2026 09:53:00 -0400

si-local-file:///var/storage/secattach/20260615/26645369.html

Form SCHEDULE 13D/A Humacyte, Inc. Filed by: FRESENIUS MEDICAL CARE HOLDINGS INC /NY/

Mon, 15 Jun 2026 09:53:00 -0400

si-local-file:///var/storage/secattach/20260615/26645369.html

Humacyte reports bioengineered blood vessel beats standard care for women on dialysis

Mon, 15 Jun 2026 08:00:56 -0400

Humacyte Inc. (NASDAQ: HUMA) presented results from its Phase 3 V012 study showing its bioengineered blood vessel outperformed the current standard of care for women on dialysis. The data was presented at the Society for Vascular Surgery's Vascular Annual Meeting in Boston.

Women who received Humacyte's acellular tissue engineered vessel (ATEV) averaged 220 catheter-free days over the first year, compared with 129 days for women who received an arteriovenous fistula, the current standard of care. The difference was statistically significant with a p-value of 0.00070.

The study also showed lower infection rates for ATEV patients, with about 6 infections per 100 patient

Humacyte reports bioengineered blood vessel beats standard care for women on dialysis

Mon, 15 Jun 2026 08:00:56 -0400

The study also showed lower infection rates for ATEV patients, with about 6 infections per 100 patient

Humacyte reports bioengineered blood vessel beats standard care for women on dialysis

Mon, 15 Jun 2026 08:00:56 -0400

The study also showed lower infection rates for ATEV patients, with about 6 infections per 100 patient

Humacyte reports bioengineered blood vessel beats standard care for women on dialysis

Mon, 15 Jun 2026 08:00:56 -0400

The study also showed lower infection rates for ATEV patients, with about 6 infections per 100 patient

Humacyte reports bioengineered blood vessel beats standard care for women on dialysis

Mon, 15 Jun 2026 08:00:56 -0400

The study also showed lower infection rates for ATEV patients, with about 6 infections per 100 patient

Humacyte reports bioengineered blood vessel beats standard care for women on dialysis

Mon, 15 Jun 2026 08:00:56 -0400

The study also showed lower infection rates for ATEV patients, with about 6 infections per 100 patient

Humacyte reports bioengineered blood vessel beats standard care for women on dialysis

Mon, 15 Jun 2026 08:00:56 -0400

The study also showed lower infection rates for ATEV patients, with about 6 infections per 100 patient

Humacyte reports bioengineered blood vessel beats standard care for women on dialysis

Mon, 15 Jun 2026 08:00:56 -0400

The study also showed lower infection rates for ATEV patients, with about 6 infections per 100 patient

Humacyte reports bioengineered blood vessel beats standard care for women on dialysis

Mon, 15 Jun 2026 08:00:56 -0400

The study also showed lower infection rates for ATEV patients, with about 6 infections per 100 patient

Humacyte reports bioengineered blood vessel beats standard care for women on dialysis

Mon, 15 Jun 2026 08:00:56 -0400

The study also showed lower infection rates for ATEV patients, with about 6 infections per 100 patient

Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting

Mon, 15 Jun 2026 08:00:00 -0400

– Positive results from the V012 Phase 3 study were presented at the Society for Vascular Surgery's Vascular Annual Meeting in Boston –

– Women who received Humacyte's ATEV experienced an average of three more months without a dialysis catheter than women who received AV fistula, the current standard of care –

– Company to hold investor event today, June 15th, at 5:00 p.m. ET –